A new hydrogel pairs silk protein with a plant compound
Researchers at the Terasaki Institute for Biomedical Innovation have reported laboratory results for an injectable hydrogel designed to support soft-tissue repair. The material combines silk fibroin, a protein derived from silkworm cocoons, with puerarin, a bioactive compound found in the root of the kudzu plant. In the reported tests, the hydrogel supported complete wound closure within 72 hours in cell-based wound-healing experiments.
The work, published in ACS Omega, addresses a persistent problem in regenerative medicine: how to place a wound-repair material deep in tissue without surgery while still giving it the mechanical strength and biological compatibility needed to help healing. Many existing biomaterials either need to be implanted surgically, do not conform well to soft tissue, or fail to create an environment that strongly supports cell growth.
The Terasaki team focused on a formulation that could be delivered through a fine needle, then recover its gel structure after injection. That combination matters because minimally invasive delivery is often as important as the material itself. A biomaterial that performs well in a dish but cannot be placed easily and safely in the body is less likely to translate into clinical use.
Why silk fibroin and puerarin were combined
Silk fibroin has long attracted interest in biomedical engineering because it is generally well tolerated by the body and can be processed into different forms, including gels and scaffolds. On its own, however, the challenge is tuning its internal structure so that it is strong enough to remain stable while still flexible enough for soft tissue.
Puerarin was introduced as the second ingredient because it brings a different set of properties. The compound is described in the study as having anti-inflammatory and antioxidant characteristics, both of which are relevant in wound repair. But the new paper is not just arguing that puerarin adds biological activity. It also reports a structural role: the compound strengthened the hydrogel network through hydrogen bonding.
That is important because it suggests the researchers did not simply mix two promising ingredients together. They found that puerarin contributed to the internal architecture of the gel, increasing density and mechanical stability as its concentration rose from 1% to 5% in the tested formulations. At the same time, the underlying protein structure of the silk fibroin was reported to remain unchanged.
What the lab tests showed
The study systematically evaluated five versions of the hydrogel, each with a fixed amount of silk fibroin and a different puerarin concentration. Across those formulations, the researchers reported several features that would be considered encouraging at an early-stage materials screen.
First, the hydrogel was injectable through a 27-gauge needle under pressure and then recovered its gel-like form after delivery. That indicates the material can behave as a fluid during injection while maintaining a stable network afterward, a useful characteristic for localized treatment in hard-to-reach tissue sites.
Second, human skin cells exposed to the material showed cell viability above 95% from day 1 in the reported in vitro testing. No signs of toxicity were observed across the tested formulations. For a wound-repair material, low toxicity is not a bonus feature; it is a threshold requirement, since a dressing or scaffold that harms surrounding cells would undermine the healing process it is supposed to support.
Third, the wound-healing assays produced the headline result: cells cultured with the hydrogels achieved complete wound closure within 72 hours across all tested formulations. The version with the highest puerarin concentration was especially fast early on, reaching about 60% wound closure within the first 24 hours, according to the report.
Why the result matters
These findings are notable because wound care remains a large and stubborn clinical challenge. Hard-to-heal wounds, injuries in anatomically difficult locations, and tissue damage that requires a material to conform closely to a soft surface all put pressure on existing treatment options. An injectable hydrogel that can be delivered through a small needle, avoid obvious toxicity, and support rapid closure in lab models is the kind of platform researchers want to see at the start of a translational pathway.
The material also sits at the intersection of two active trends in biomaterials research. One is the push toward minimally invasive delivery, which can reduce procedural burden and expand where a therapy can be used. The other is the use of naturally derived components that may offer a favorable balance of compatibility and performance.
That does not mean the hydrogel is close to routine medical use. The reported results are laboratory findings, not evidence from human trials. Cell viability tests and in vitro wound-closure assays are useful screening tools, but they do not capture the full complexity of real wounds, where blood flow, immune response, infection risk, tissue mechanics, and patient variability all shape outcomes.
The main limitation is also the main next step
The strongest claim supported by the available source text is that this hydrogel performed well in laboratory testing. That is meaningful, but it is not the same as showing that it improves healing in animals or people. The next development stages would typically involve more advanced preclinical evaluation to determine how the material behaves in living tissue over time, how it degrades, whether it triggers unwanted immune reactions, and whether its mechanical and biological performance holds up outside simplified lab conditions.
Even so, the study provides a concrete signal that formulation design matters. Increasing puerarin concentration did not just change one cosmetic property of the gel. It appeared to produce denser internal networks and higher mechanical stability while preserving injectability and supporting rapid wound closure. That gives the researchers a clearer path for optimizing the material rather than starting from a vague proof of concept.
For the broader field, that is arguably the most useful takeaway. Many wound-care biomaterials promise biocompatibility or drug-delivery potential, but fewer demonstrate a practical combination of needle delivery, structural recovery, cell compatibility, and measurable wound-closure performance in one platform. The Terasaki group’s hydrogel appears to check those early boxes in vitro.
If later studies confirm the same pattern in more realistic models, the material could become part of a wider move toward injectable regenerative therapies that are easier to place and better matched to delicate tissue environments. For now, the result is best understood as a promising early-stage biomaterials advance: not a finished therapy, but a carefully engineered platform with enough laboratory evidence to justify deeper testing.
This article is based on reporting by Phys.org. Read the original article.
Originally published on phys.org
